3. To ask the Scottish Government whether it plans to review beta blocker prescribing recommendations following a study recently published in The Journal of the American Medical Association suggesting that beta blockers did not prolong the lives of patients. (S4O-01518)
Alex NeilSNPThe Cabinet Secretary for Health and Wellbeing · Airdrie and Shotts
The safety, efficacy and quality of medicines is currently a reserved matter, with the Medicines and Healthcare products Regulatory Agency being the United Kingdom-wide authority responsible for such issues. I understand that there are no current plans to amend beta blocker prescribing recommendations as a result of the study.
Beta blockers were hailed as one of the great medical advances of the 20th century. Their inventor, Scotsman James Black, won the Nobel prize in medicine in 1988.
The cabinet secretary will be aware that the journal’s study involved some 45,000 patients over 42 months, and it showed that beta blockers do not reduce the risk of heart attacks or strokes, or deaths from either. Given that the study was similar to another recently published in the Journal of American Geriatrics Society, does he share my concern that tens of thousands of Scots may be taking beta blockers needlessly when another form of treatment may be more appropriate?
Alex NeilSNPThe Cabinet Secretary for Health and Wellbeing · Airdrie and Shotts
I understand from the MHRA that the safety and efficacy of beta blockers and their licence indications, including use following heart attack, have been clearly demonstrated through randomised clinical trials. Clinical guidance in the UK has a strong evidence base and provides clear recommendations on the place of beta blockers in the treatment of hypertension and on the most clinically effective use of beta blockers following a heart attack.
The United States study has a number of methodological implications that can influence findings and, furthermore, it does not reflect how beta blockers are used routinely in UK clinical practice. Therefore, the study’s findings are not considered to have significant implications for the use of beta blockers in the UK, and it is unlikely that beta blocker prescribing recommendations will need to be altered in the light of those findings.
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.